Immune thrombocytopenia (ITP) is an acquired autoimmune condition whereby autoantibodies against platelets lead to increased platelet clearance, suppression of megakaryocytopoiesis, and subsequent thrombocytopenia. 1, 2 ITP is associated with increased bleeding risk, and the primary goal of therapy is to prevent clinically significant bleeding.
Steroids, and in some cases intravenous immunoglobulin, are recommended first-line therapies. 3 However, many patients relapse and alternative therapies including splenectomy, rituximab, and thrombopoietin (TPO) receptor agonists are available for second-line treatment.
Romiplostim is a TPO receptor agonist that binds to and activates the TPO receptor (cMpl) on megakaryocytes and their precursors, resulting in increased platelet production. 4 Romiplostim is approved for the treatment of chronic ITP. Approximately 60-90% of patients respond favorably to romiplostim, but in early studies few maintained platelet counts >50x10 9 /L upon discontinuation. [5] [6] Therefore, although romiplostim is clearly effective in durably raising platelet counts in most patients with minimal safety concerns over at least five years, [7] [8] there is a perception that indefinite treatment is required.
We sought to explore the real-world use of romiplostim with regard to treatment duration and frequency of treatment-free remission. We extracted patient information from databases of all ITP patients seen by the investigators at Massachusetts General Hospital, Boston, Massachusetts and Princess Alexandra Hospital, Brisbane, Australia. All patients had a diagnosis of chronic ITP as defined by American Society of Hematology criteria 9 and received romiplostim therapy for at least 6 months. Patients were managed according to standard procedures dictating dosing frequency and changes. Platelet counts were measured approximately once a week until a stable dose was achieved and then measured approximately once monthly. Treatment-free remission was defined as the ability of a patient to discontinue romiplostim without subsequent need for other disease-modifying therapies.
A total of 423 ITP patients were treated, and 116 (27%) received a TPO receptor agonist.
43 (10%) received romiplostim for more than six months and served as the study population.
There were no significant differences in patient characteristics or outcomes between the two centers. Patient demographics are presented in Table 1 . Most patients were women and median age romiplostim initiation was 50 years. Most had chronic disease with a median time of 2 Of the 43 patients, 12 (28%) were able to discontinue romiplostim successfully (without need for further therapy aside from occasional prednisone in one patient). Characteristics of patients who experienced a treatment-free remission upon romiplostim discontinuation are shown in Table 2 . Two of these 12 patients had undergone splenectomy while on romiplostim without durable significant increase in post-operative platelet count; romiplostim was continued after splenectomy and later discontinued successfully. Median (range) duration of romiplostim therapy prior to successful discontinuation was 1 Table 2) .
Treatment-free remissions were more likely in patients who had undergone splenectomy prior to romiplostim than in those who failed therapy (p=.05). Median platelet count at the initiation of romiplostim was slightly higher in patients with treatment-free remissions than in those still on therapy or who those who failed, and there was a higher percentage of females in patients with treatment-free remissions than those who failed treatment; neither difference was Whether some of these patients could have discontinued therapy could not be determined from the data collected. Six patients (14%) discontinued romiplostim for treatment failure (inability to maintain platelet counts >50x10 9 /L and/or bleeding). None had undergone splenectomy prior to romiplostim; all six eventually underwent splenectomy while still on romiplostim or soon after discontinuation.
Six patients (14%) died while on romiplostim: two of myocardial infarction, one of pneumonia, one of progressive multifocal leukoencephalopathy, one from a pulmonary embolism, and one from an unknown cause. All had pre-existing medical comorbidities. Platelet counts at or near the time of death were available for 5 of the 6 patients including: 526x10 9 (2 weeks before death, at which point romiplostim was held), 154x10 9 2-3 days prior to death, <5x10 9 the day prior to death, 314x10 9 2-3 days prior to death, and 102x10 9 at the time of death. /L and 28x10 9 /L), and one concomitant deep venous thrombosis and pulmonary embolism (812x10 9 /L). This last patient developed VTE three weeks after splenectomy; splenectomy was felt to be a major risk factor for both thrombocytosis and VTE.
The TPO receptor agonists are of significant benefit in the symptomatic treatment of ITP, but as there is no defined treatment "course" for these agents, treatment is often continued indefinitely. This presents a challenge in terms of patient quality of life, decision to undergo splenectomy, potential risk of bone marrow fibrosis, 10 risk of arterial and venous thromboembolism, and health care costs. We investigated the concept and frequency of a "remission" after TPO receptor agonist therapy and delineate the term "treatment-free remission"
to indicate that the patient no longer requires active ITP therapy and is considered at low risk for subsequent bleeding. Of those patients treated with romiplostim for over six months, 12/43 (28%) were able to obtain a treatment-free remission after a median of 1 . 8 years. 6 Our data in no way suggests an absence of ITP disease activity in all patients with treatment-free remission. When assessed by the international consensus criteria, 11 all subjects had a response (platelets >30x10 9 /L) and 10/12 had a complete response (platelets >100x10 9 /L), but only 6/12 had platelet counts that would be considered normal especially after splenectomy.
These data also challenge more optimistic reports of sustained remission rates of 53% after discontinuation of eltrombopag and 48-57% after discontinuation of romiplostim. [12] [13] [14] While these studies had similar patient populations including percent of patients undergoing splenectomy prior to TPO receptor agonist treatment, treatment duration varied and in some cases was much shorter than in our study. Our data are similar to findings from a recent study of 75 patients with newly diagnosed ITP treated with romiplostim, where 32% of patients achieved a remission (defined as a platelet count >50x10 9 /L for 24 consecutive weeks with no ITP treatments). 15 In these studies, some patients experienced remission after very brief exposure to TPO receptor agonist, in some cases less than 1 month. Spontaneous remissions occur commonly in ITP patients and their association with brief exposure to TPO receptor agonists is unclear and may simply be a coincidence.
As with all retrospective studies, our data must be interpreted in the context of potential biases, including our choice to focus on romiplostim (rather than all TPO receptor agonists).
There were no uniform rules regarding when to discontinue romiplostim. We cannot know the final treatment response in patients who died of non-ITP related causes while still on romiplostim.
Our data reflects the nature of "real-life" treatment of a large number of ITP patients at two major centers. These data suggest that TPO receptor agonist treatment may not be indefinite in ~30% of patients and helps guide the timing of other therapies, including splenectomy, in
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Figure 1: Percentage of patients able to achieve treatment-free remission Treatment-free remission was defined as the ability of a patient to discontinue romiplostim without subsequent need for future disease-modifying therapies. This does not include patients who died while on romiplostim therapy.
